• Artículo
      Icon

      Initial experience with golimumab in clinical practice for ulcerative colitis 

      Castro Laria, Luisa; Argüelles Arias, Federico; García Sánchez, Valle; Benítez, José Manuel; Fernández Pérez, Ramón; Trapero Fernández, Ana María; Herrerías Gutiérrez, Juan Manuel (Aran Ediciones S.A., 2016)
      Background: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis. Purpose: To ...